General MedicationsORALStandard
TIROSINT
LEVOTHYROXINE SODIUM
Standard Dose
0.0625MG
Max Dose
Refer to approved labeling
Primary Use
Review priority: N/A Marketing status: Prescription
Summary
Approval overview TIROSINT is listed in Drugs@FDA under application 021924 (NDA).
Review priority: N/A Marketing status: Prescription Active ingredient LEVOTHYROXINE SODIUM Form and strength CAPSULE;ORAL - 0.0625MG Sponsor IBSA Submission history Latest submission status date: 2022-06-22 00:00:00.
Structured Monograph
Clinical summary
Approval overview TIROSINT is listed in Drugs@FDA under application 021924 (NDA). Review priority: N/A Marketing status: Prescription Active ingredient LEVOTHYROXINE SODIUM Form and strength CAPSULE;ORAL - 0.0625MG Sponsor IBSA Submission history Latest submission status date: 2022-06-22 00:00:00. Submission type: SUPPL.
Monitoring
- • Marketing status: Prescription
- • Review priority: N/A
Interaction Notes
- No interaction notes stored yet.